[go: up one dir, main page]

IL161744A0 - Combination therapy comprising zd6474 and a taxane - Google Patents

Combination therapy comprising zd6474 and a taxane

Info

Publication number
IL161744A0
IL161744A0 IL16174402A IL16174402A IL161744A0 IL 161744 A0 IL161744 A0 IL 161744A0 IL 16174402 A IL16174402 A IL 16174402A IL 16174402 A IL16174402 A IL 16174402A IL 161744 A0 IL161744 A0 IL 161744A0
Authority
IL
Israel
Prior art keywords
taxane
combination therapy
therapy
combination
Prior art date
Application number
IL16174402A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL161744A0 publication Critical patent/IL161744A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16174402A 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane IL161744A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (1)

Publication Number Publication Date
IL161744A0 true IL161744A0 (en) 2005-11-20

Family

ID=9925430

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16174402A IL161744A0 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
IL161744A IL161744A (en) 2001-11-08 2004-05-03 Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161744A IL161744A (en) 2001-11-08 2004-05-03 Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds

Country Status (22)

Country Link
US (2) US20050043395A1 (es)
EP (1) EP1446124B1 (es)
JP (1) JP4694127B2 (es)
KR (1) KR100959607B1 (es)
CN (1) CN1298328C (es)
AR (1) AR037346A1 (es)
AT (1) ATE335488T1 (es)
AU (1) AU2002337382B2 (es)
BR (1) BR0213906A (es)
CA (1) CA2464758C (es)
CY (1) CY1106259T1 (es)
DE (1) DE60213845T2 (es)
DK (1) DK1446124T3 (es)
ES (1) ES2269769T3 (es)
GB (1) GB0126879D0 (es)
IL (2) IL161744A0 (es)
MX (1) MXPA04004355A (es)
NO (1) NO328048B1 (es)
NZ (1) NZ532525A (es)
PT (1) PT1446124E (es)
WO (1) WO2003039551A1 (es)
ZA (1) ZA200403455B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676845B1 (en) 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DK1274692T3 (da) 2000-04-07 2006-10-30 Astrazeneca Ab Quinazolinforbindelser
US7268230B2 (en) * 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
ES2300619T3 (es) 2002-11-04 2008-06-16 Astrazeneca Ab Derivados de quinolina como inhibidores de src tirosina quinasa.
WO2004071397A2 (en) * 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
ATE478671T1 (de) * 2003-07-10 2010-09-15 Astrazeneca Ab Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
JP2008504292A (ja) * 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
JP2008514577A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ｚｄ６４７４及びイマチニブを含んでなる組合せ
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
JP5167144B2 (ja) * 2005-12-22 2013-03-21 アストラゼネカ アクチボラグ 併用療法
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
BRPI0912170A2 (pt) * 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
AU2021409515A1 (en) * 2020-12-22 2023-07-06 Hanmi Pharmaceutical Co., Ltd. Novel quinazoline derivatives as SOS1 inhibitors and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EP0910382B1 (en) * 1996-04-26 2003-06-11 Magainin Pharmaceuticals Inc. Squalamine in combination with other anti-cancer agents for treating tumors
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
WO2000050059A1 (en) * 1999-02-24 2000-08-31 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
HK1045700B (zh) * 1999-04-28 2007-07-27 德克萨斯大学董事会 用於通过选择性抑制vegf来治疗癌症的组合物和方法
EP1676845B1 (en) * 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004071397A2 (en) * 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
ATE478671T1 (de) * 2003-07-10 2010-09-15 Astrazeneca Ab Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
JP2008514577A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ｚｄ６４７４及びイマチニブを含んでなる組合せ
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP5167144B2 (ja) * 2005-12-22 2013-03-21 アストラゼネカ アクチボラグ 併用療法
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
US20120252827A1 (en) 2012-10-04
NZ532525A (en) 2006-11-30
JP4694127B2 (ja) 2011-06-08
NO328048B1 (no) 2009-11-16
MXPA04004355A (es) 2004-08-11
US20050043395A1 (en) 2005-02-24
PT1446124E (pt) 2006-12-29
DK1446124T3 (da) 2006-11-13
DE60213845D1 (de) 2006-09-21
AR037346A1 (es) 2004-11-03
HK1068546A1 (en) 2005-04-29
NO20042365L (no) 2004-06-07
WO2003039551A1 (en) 2003-05-15
DE60213845T2 (de) 2007-03-29
CY1106259T1 (el) 2011-06-08
BR0213906A (pt) 2004-08-31
EP1446124A1 (en) 2004-08-18
KR100959607B1 (ko) 2010-05-27
CN1298328C (zh) 2007-02-07
AU2002337382B2 (en) 2008-06-12
EP1446124B1 (en) 2006-08-09
KR20050043779A (ko) 2005-05-11
ZA200403455B (en) 2005-08-29
CA2464758A1 (en) 2003-05-15
CA2464758C (en) 2010-09-28
GB0126879D0 (en) 2002-01-02
ES2269769T3 (es) 2007-04-01
CN1612738A (zh) 2005-05-04
JP2005511597A (ja) 2005-04-28
ATE335488T1 (de) 2006-09-15
IL161744A (en) 2012-01-31

Similar Documents

Publication Publication Date Title
IL161744A0 (en) Combination therapy comprising zd6474 and a taxane
GB0111872D0 (en) Therapeutic agents and methods
EP1463438A4 (en) ENDOMURAL THERAPY
PL370563A1 (en) Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
GB0114014D0 (en) Compostion and use
HUP0600233A3 (en) A combination comprising combretastatin and anticancer agents
GB0119025D0 (en) Compounds and their therapeutic use
GB0108485D0 (en) Combination therapy
GB0101933D0 (en) Therapy
SI1446124T1 (sl) Kombinacijska terapija, ki obsega ZD6474 in taksan
HU0200253D0 (en) Combination therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
GB0128122D0 (en) Therapeutic use
GB0123991D0 (en) New therapeutic use
GB0201615D0 (en) Compounds and their therapeutic use
GB0128512D0 (en) Compounds and their therapeutic use
GB0124029D0 (en) Combination therapy
GB0108821D0 (en) Therapy
GB0108816D0 (en) Therapy
GB0108817D0 (en) Therapy
GB0130679D0 (en) Medicaments and novel compounds
GB0130785D0 (en) Medicaments and novel compounds
GB0130678D0 (en) Medicaments and novel compounds
GB0128126D0 (en) Therapeutic use